Phaseline

Companies › Consun Pharmaceutical Group

Consun Pharmaceutical Group: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Ophthalmology, Genitourinary; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SK-09–Phase 1FSGSApr 2027
SK-08–Phase 1Chronic Kidney Disease(CKD)–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07021157SK-08Phase 1Chronic Kidney Disease(CKD)GenitourinaryAug 2025
NCT07267026SK-09Phase 1FSGSOphthalmologyApr 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.